A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 3-4, 2013, Pages 290-302

  Wang, Jian ^a,b   Xia, Sumei ^b   Xue, Weifang ^b   Wang, Dawei ^c   Sai, Yang ^b   Liu, Li ^a   Liu, Xiaodong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Hutchison Medipharma Ltd   (China)

^c Jiangsu Province Academy of Traditional Chinese Medicine   (China)

Author keywords

Auto inhibition; CYP3A; Drug drug interaction; pharmacokinetic model; Semi physiologically based; Stereoselective pharmacokinetics; Verapamil

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYCLOSPORIN A; CYTOCHROME P450 3A; DEALKYLVERAPAMIL; ERLOTINIB; KETOCONAZOLE; MIDAZOLAM; NORVERAPAMIL; PHENACETIN; SIMVASTATIN; VERAPAMIL;

ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INACTIVATION; LIVER MICROSOME; PRIORITY JOURNAL; SIMULATION; STEREOCHEMISTRY; SUSTAINED RELEASE PREPARATION; TABLET;

AUTO-INHIBITION; CYP3A; DRUG-DRUG INTERACTION; SEMI-PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL; STEREOSELECTIVE PHARMACOKINETICS; VERAPAMIL;

CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; INTESTINE, SMALL; LIVER; MICROSOMES, LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; SIMVASTATIN; STEREOISOMERISM; STOMACH; VERAPAMIL;

EID: 84884520487     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.07.012     Document Type: Article

References (51)

1. R. Andersin Solubility and acid-base behavior of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent software J. Pharm. Bio. Ana. 9 1991 451 455
2. R.P. Austin, P. Barton, S.L. Cockroft, M.C. Wenlock, and R.J. Riley The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties Drug Metab. Dispos. 30 2002 1497 1503 (Pubitemid 35397059)
3. J.T. Backman, K.T. Olkkola, K. Aranko, J.J. Himberg, and P.J. Neuvonen Dose of midazolam should be reduced during diltiazem and verapamil treatments Br. J. Clin. Pharmacol. 37 1994 221 225 (Pubitemid 24212179)
4. R. Badhan, J. Penny, A. Galetin, and J.B. Houston Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption J. Pharm. Sci. 98 2009 2180 2197
5. D. Busse, J. Cosme, P. Beaune, H.K. Kroemer, and M. Eichelbaum Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans Naunyn Schmiedebergs Arch Pharmacol. 353 1 1995 116 121 (Pubitemid 26009826)
6. R.A. Carr, F.A. Pasutto, J.A. Longstreth, and R.T. Foster Stereospecific determination of the in vitro dissolution of modified release formulations of (±)-verapamil Chirality 5 1993 443 447 (Pubitemid 23293274)
7. Y. Chen, L.L. Liu, M. Monshouwer, and A.J. Fretland Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interaction Drug Metab. Dispos. 39 2011 2085 2092
8. J.Y. Chien, A. Lucksiri, C.S. Ernest 2nd, J.C. Gorski, S.A. Wrighton, and S.D. Hall Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole Drug Metab. Dispos. 34 2006 1208 1219 (Pubitemid 43922328)
9. M. Eichelbaum, G. Mikus, and B. Vogelgesang Pharmacokinetics of (+)-, (-) - and (±)-verapamil after intravenous administration Br. J. Clin. Pharmac. 17 1984 453 458
10. F. Fenneteau, P. Poulin, and F. Nekka Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates J. Pharm. Sci. 99 2009 486 514
11. M. Gertz, A. Harrison, J.B. Houston, and A. Galetin Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Drug Metab. Dispos. 38 2010 1147 1158
12. M. Gertz, J.B. Houston, and A. Galetin Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction Drug Metab. Dispos. 2011 10.1124/dmd.111.039248
13. M. Gertz, P.J. Kilford, J.B. Houston, and A. Galetin Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations Drug Metab. Dispos. 36 2008 535 542 (Pubitemid 351397979)
14. D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, G. Chen, J.L. Weemhoff, C. Jen, C.J. Kelley, B.W. LeDuc, and M.A. Zinny Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice Clin. Pharmacol. Ther. 74 2003 121 129 (Pubitemid 36951809)
15. S.W. Grimm, H.J. Einolf, S.D. Hall, K. He, H.K. Lim, K.H. Ling, C. Lu, A.A. Nomeir, E. Seibert, K.W. Skordos, G.R. Tonn, R. Van Horn, R.W. Wang, Y.N. Wong, T.J. Yang, and R.S. Obach The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America Drug Metab Dispos. 37 2009 1355 1370
16. L. Guzik, W. Mrozik, and W. Kamysz Determination of simvastatin in pharmaceutical dosage forms by optimized and validated method using HPLC/UV Croat. Chem. Acta. 83 2010 371 377
17. P.C. Ho, K. Ghose, and D. Saville Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers Eur. J. Clin. Pharmacol. 56 2000 693 698 (Pubitemid 32204491)
18. E.M. Howgate, K. Rowland-Yeo, N.J. Proctor, G.T. Tucker, and A. Rostami-Hodjegan Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability Xenobiotica 36 2006 473 497 (Pubitemid 43890728)
19. K. Ito, K. Ogihara, S. Kanamitsu, and T. Itoh Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes Drug Metab. Dispos. 31 2003 945 954 (Pubitemid 36759066)
20. T.A. Jacobson Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin and atorvastatin when coadministered with cytochrome P450 inhibitors Am. J. Cardiol. 94 2004 1140 1146 (Pubitemid 39424216)
21. J.A. Johnson, and W.S. Akers Influence of metabolites on protein binding of verapamil enantiomers Br. J. Clin. Pharmac. 39 1995 536 538
22. T. Kantola, K.T. Kivisto, and P.J. Neuvonen Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations Clin. Pharmacol. Ther. 64 1998 177 182 (Pubitemid 28423853)
23. A. Karim, and A. Piergies Verapamil stereoisomerism: enantiomeric ratio is plasma dependent on peak concentrations, oral input rate or both Clin. Pharmacol. Ther. 58 1995 174 184
24. H.K. Kroemer, H. Echizen, H. Heidemann, and M. Eichelbaum Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects J. Pharmacol. Exp. Ther. 260 1992 1052 1057
25. G.L. Lemma, Z. Wang, M.A. Hamman, N.A. Zaheer, J.C. Gorski, and S.D. Hall The effect of short- and long-term administration of verapamil on the disposition of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates Clin. Pharmacol. Ther. 79 2006 218 230
26. L. Maggi, G. Massolini, E. De Lorenzi, U. Conte, and G. Caccialanza Evaluation of stereoselective dissolution of verapamil hydrochloride from matrix tablets press-coated with chiral excipients Int. J. Pharm. 136 1996 43 52 (Pubitemid 26200737)
27. G. Mikus, M. Eichelbaum, and C. Fischer Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action J. Pharmacol. Exp. Ther. 253 1990 1042 1048 (Pubitemid 20209361)
28. R.S. Obach Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 27 1999 1350 1359
29. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh, J.D. Perkins, and K.E. Thummel Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 283 1997 1552 1562 (Pubitemid 28016533)
30. N. Perdaems, H. Blasco, C. Vinson, M. Chenel, S. Whalley, F. Cazade, and F. Bouzom Predictions of metabolic drug-drug interactions using physiologically based modeling-two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil Clin. Pharmacokinet. 49 2010 239 258
31. M.D. Perloff, L.L. Von Moltke, M.H. Court, T. Kotegawa, R.I. Shader, and D.J. Greenblatt Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms J. Pharmacol. Exp. Ther. 292 2000 618 628 (Pubitemid 30067425)
32. P. Poulin, R.D.O. Jones, H.M. Jones, C.R. Gibson, M. Rowland, J.Y. Chien, B.J. Ring, K.K. Adkison, M.S. Ku, H. He, R. Voppugalla, P. Marathe, V. Fisher, S. Dutta, V.K. Sinha, T. Björnsson, Thierry Lave, and J.W.T. Yates PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach J. Pharm. Sci. 2011 1 31
33. P. Poulin, and F.P. Theil Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution J. Pharm. Sci. 91 2002 126 159
34. M.A. Robinson, and R. Mehvar Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding Biopharm. Drug Dispos. 17 1996 577 587 (Pubitemid 26319896)
35. R.A. Roboson, M. Fraenkel, L.J. Barratt, and D.J. Birkett Cyclosporin-verapamil interaction Br. J. Clin. Pharmac. 25 1988 402 403
36. T. Rodgers, D. Leahy, and M. Rowland Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 94 2005 1259 1276 (Pubitemid 40904190)
37. T. Rodgers, and M. Rowland Mechanistic approaches to volume of distribution predictions: understanding the processes Pharm. Res. 24 2007 918 933 (Pubitemid 46675393)
38. K. Rowland-Yeo, M. Jamei, J.S. Yang, G.T. Tucker, and A. Rostami-Hodjegan Physiologically based mechanistic modeling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam Eur. J. Pharm. Sci. 39 2010 298 309
39. Rowland-Yeo, K., Rostami-Hodjegan, A., and Tucker, G.T., 2003. Abundance of cytochrome P450 in human liver: a meta-analysis. British Pharmacological Society winter meeting, university of London.
40. K. Rowland-Yeo, R.L. Walsky, M. Jamei, A. Rostami-Hodjegan, and G.T. Tucher Prediction of time-dependent CYP3A drug-drug interactions by physiologically based pharmacokinetic modeling: impact of inactivation parameters and enzyme turnover Eur. J. Pharm. Sci. 43 2011 160 173
41. R. Sandström, A. Karlsson, L. Knutson, and H. Lennernäs Jejunal absorption and metabolism of R/S-verapamil in humans Pharm. Res. 15 1998 856 862 (Pubitemid 28307826)
42. J. Schmider, D.J. Greenblatt, J.S. Harmatz, and R.I. Shader Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation Br. J. Clin. Pharmacol. 41 1996 593 604 (Pubitemid 26184682)
43. D.G. Shand, S.C. Hammill, L. Aanonsen, and E.L.C. Pritchett Reduced verapamil clearance during long-term oral administration Clin. Pharmacol. Ther. 30 1981 701 703
44. C. Tanaka, R. Kawai, and M. Rowland Dose-dependent pharmacokinetics of cyclosporine A in rats: events in tissues Drug Metab. Dispos. 28 2000 582 589 (Pubitemid 30238519)
45. T.S. Tracy, K.R. Korzekwa, F.J. Gonzalez, and I.W. Wainer Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil Br. J. Clin. Pharmacol. 47 1999 545 552 (Pubitemid 29199727)
46. G. Toffoli, I. Robieux, D. Fantin, M. Gigante, S. Frustaci, G.L. Nicolosi, M. De Cicco, and M. Boiocchi Non-linear pharmacokinetics of high-dose intraveneous verapamil Br. J. Clin. Pharmacol. 44 1997 255 260 (Pubitemid 27376252)
47. S. Vickers, C.A. Duncan, I.-W.u. Chen, A. Rosegay, and D.E. Duggan Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug Drug Metab. Dispos. 18 1989 138 145 (Pubitemid 20107705)
48. H. Vogelpoel, J. Welink, G.L. Amidon, H.E. Junginger, K.K. Midha, H. Moller, M. Olling, V.P. Shah, and D.M. Barends Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride and atenolol J. Pharm. Sci. 93 2004 1945 1956 (Pubitemid 39045477)
49. Y.H. Wang, D.R. Jones, and S.D. Hall Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites Drug Metab. Dispos. 32 2004 259 266 (Pubitemid 38176944)
50. L.X. Yu, J.R. Crison, and G.L. Amidon Compartmental transit and dispersion model analysis of small intestinal transit flow in humans Int. J. Pharm. 140 1996 111 118 (Pubitemid 26276720)
51. X. Zhang, S.K. Quinney, J.C. Gorski, D.R. Jones, and S.D. Hall Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolites Drug Metab. Dispos. 37 2009 1587 1597